AR030741A1 - Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa - Google Patents

Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa

Info

Publication number
AR030741A1
AR030741A1 ARP010104370A ARP010104370A AR030741A1 AR 030741 A1 AR030741 A1 AR 030741A1 AR P010104370 A ARP010104370 A AR P010104370A AR P010104370 A ARP010104370 A AR P010104370A AR 030741 A1 AR030741 A1 AR 030741A1
Authority
AR
Argentina
Prior art keywords
derivatives
amino
inhibitors
nitrical
heptinoico
Prior art date
Application number
ARP010104370A
Other languages
English (en)
Inventor
James A Sikorski
Barnett S Pitzele
Mark A Massa
Ronald Hage
Margaret L Grapperhaus
Lijuan Jane Wang
Donald W Hansen Jr
Ronald Keith Webber
Arija Bergmanis
Steven Kramer
E Ann Halliman
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR030741A1 publication Critical patent/AR030741A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Abstract

Derivados de ácido 2-amino-2-alquil-5 heptenoico y heptinoico y su uso terapéutico, en particular su uso como inhibidores de oxido nítrico sintetasa.
ARP010104370A 2000-09-15 2001-09-14 Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa AR030741A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23268300P 2000-09-15 2000-09-15

Publications (1)

Publication Number Publication Date
AR030741A1 true AR030741A1 (es) 2003-09-03

Family

ID=22874118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104370A AR030741A1 (es) 2000-09-15 2001-09-14 Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa

Country Status (27)

Country Link
US (2) US6951889B2 (es)
EP (1) EP1317421B1 (es)
JP (1) JP5009480B2 (es)
KR (1) KR100840981B1 (es)
CN (1) CN1301966C (es)
AR (1) AR030741A1 (es)
AT (1) ATE289587T1 (es)
AU (2) AU2001290883A1 (es)
BR (1) BR0113925A (es)
CA (1) CA2421504C (es)
CY (1) CY1106056T1 (es)
CZ (1) CZ2003646A3 (es)
DE (1) DE60109046T2 (es)
DK (1) DK1317421T3 (es)
EA (1) EA006244B1 (es)
ES (1) ES2238477T3 (es)
HK (1) HK1062910A1 (es)
IL (2) IL154841A0 (es)
MX (1) MXPA03002207A (es)
MY (1) MY131964A (es)
NO (1) NO20031140L (es)
NZ (1) NZ524562A (es)
PL (1) PL207391B1 (es)
PT (1) PT1317421E (es)
SI (1) SI1317421T1 (es)
TW (1) TWI290130B (es)
WO (1) WO2002022562A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AU2003234606A1 (en) * 2002-05-16 2003-12-02 Pharmacia Corporation Using a selective iNOS inhibitor for the treatment of respiratory diseases and conditions
EP1505972A2 (en) * 2002-05-16 2005-02-16 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
EP1528921A2 (en) * 2002-08-02 2005-05-11 Pharmacia Corporation Methods for treatment and prevention of gastrointestinal conditions
EP1534668B1 (en) * 2002-08-23 2012-05-02 Pharmacia Corporation Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CN101193894A (zh) * 2005-06-09 2008-06-04 马林克罗特公司 通过制备色谱法分离和纯化纳曲酮的方法
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US9895324B2 (en) * 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
EP3398941A1 (en) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
PT751930E (pt) * 1994-03-24 2000-04-28 Searle & Co Derivados amidino uteis como inibidores da sintetase de oxido nitrico
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
ES2249919T3 (es) 1998-10-27 2006-04-01 Abbott Laboratories Inhibidores de la biosintesis de prostaglandina endoperoxido h sintasa.

Also Published As

Publication number Publication date
MXPA03002207A (es) 2003-06-24
TWI290130B (en) 2007-11-21
CY1106056T1 (el) 2011-04-06
JP5009480B2 (ja) 2012-08-22
IL154841A (en) 2010-12-30
ATE289587T1 (de) 2005-03-15
KR20030069167A (ko) 2003-08-25
CA2421504A1 (en) 2002-03-21
AU2001290883A1 (en) 2002-03-26
BR0113925A (pt) 2003-07-01
US20020132849A1 (en) 2002-09-19
CZ2003646A3 (cs) 2003-10-15
JP2004509099A (ja) 2004-03-25
CN1301966C (zh) 2007-02-28
SI1317421T1 (es) 2005-08-31
US20050113451A1 (en) 2005-05-26
DE60109046T2 (de) 2005-08-04
NZ524562A (en) 2005-02-25
US6951889B2 (en) 2005-10-04
NO20031140L (no) 2003-05-08
EP1317421B1 (en) 2005-02-23
EA006244B1 (ru) 2005-10-27
PL361137A1 (en) 2004-09-20
AU2007203823A1 (en) 2007-09-06
PL207391B1 (pl) 2010-12-31
NO20031140D0 (no) 2003-03-12
CA2421504C (en) 2009-11-24
ES2238477T3 (es) 2005-09-01
CN1474805A (zh) 2004-02-11
DK1317421T3 (da) 2005-06-27
IL154841A0 (en) 2003-10-31
MY131964A (en) 2007-09-28
EA200300377A1 (ru) 2003-10-30
KR100840981B1 (ko) 2008-06-24
PT1317421E (pt) 2005-07-29
AU2007203823B2 (en) 2009-06-04
EP1317421A1 (en) 2003-06-11
WO2002022562A1 (en) 2002-03-21
DE60109046D1 (de) 2005-03-31
HK1062910A1 (en) 2004-12-03

Similar Documents

Publication Publication Date Title
AR031129A1 (es) Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
ATE376434T1 (de) Injektionsgerät für mrna applikation
EA200300348A1 (ru) Спирогетероциклические нитрилы, пригодные для применения в качестве обратимо действующих ингибиторов цистеиновых протеаз
EA200300030A1 (ru) Производные гексагидро-7-1h-азепин-2-илкапроевой кислоты в качестве ингибиторов индуцибельной синтазы оксида азота
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
DK1347955T3 (da) Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere
MXPA03001785A (es) Derivados de pirazol y su uso como inhibidores de proteina cinasa.
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DOP2001000224A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
ECSP045399A (es) Derivados de quinolina e isoquinolina, un método para su preparación y su uso como inhibidores de la inflamación
CY1105097T1 (el) Χρηση παραγωγων ν-φαινυλο-2-πυριμιδιναμινης στην αγωγη εναντι φλεγμονωδων ασθενειων
DE50312034D1 (de) Liposomale glucocorticoide
AR031608A1 (es) Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR028068A1 (es) Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BR0110902A (pt) Inibidores de mmp-9/mmp-2
ATE343576T1 (de) 7-azaindolderivate als cox2-inhibitoren
AR031609A1 (es) Derivados de acido 2-amino-2-alquil-3 heptenoico y heptinoico utiles como inhibidores de oxido nitrico sintetasa
CR6302A (es) Nuevos usos farmaceuticos par inhibidores nos
TR200103398T2 (tr) íkameli fenilsikloheksankarboksamitler ve bunlarìn adenozin alìnìmìnìn inhibit”rleri olarak kullanìmì

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee